U.S. Markets close in 2 hrs 53 mins

ZIOPHARM Oncology, Inc. (ZIOP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.99+0.02 (+0.34%)
As of 1:00PM EDT. Market open.
People also watch
  • Let's test the knowledge of readers on this message board with this question. Does the immunotherapy with PD-1 inhibitors work in solid tumors?
  • Newbie asking about comparison of Northwest Bio's DCVax versus ZIOP's "superior" Veledimex + adenoviral IL-12.

    In ZIOP's case, the studies to date have only included Phase I safety and tolerability, producing ZERO evidence of tumor efficacy or improved survival (contrary to misleading company press releases). Thus, no controlled studies, only patients that have received varying doses of the activator ligand, Veledimex (lowest dose, 20mg) and the IL-12 adenoviral vector. The patients with the longest survival in ZIOP's study received the lowest dose of Veledimex + IL-12 adenoviral vector, making it possible that patients may have faired best if they had received no ZIOP therapy (i.e. a control arm that was never studied) at all. Patients in ZIOP's safety studies also went on to take various therapies post ZIOP Safety Study, thereby confounding interpretation of survival results. Lastly, ZIOP's patients were not required to limit corticosteroid use prior and post therapy as they were in the DCVAx Phase 3 study. While a theory of reduced survival with corticosteroid use has been postulated in ZIOP's study, the data shows that the longest surviving patient, the Brain Chancery Patient - you can read his blog online, received a moderate/high doses of corticosteroids post ZIOP therapy to help save his life.

    NWBO, with their PIII studies will have definitive results on activity since there patient trial includes randomly selected GBM patients and control arms. With that said, they too have limited their patient population to patients with resectable tumors. Bottom line is ZIOP's is certainly not superior to NWBO's based on available data, and ZIOP's Veledimex/IL-12 studies have a continued long and dubious road ahead. GBM a disease that is notoriously difficult to treat,
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • In case you missed it: CLLS continues to impress with additional CRISPR intellectual property for use in gene-edited T-Cell technology.
  • Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute.


  • Newbie here. So, can I hear some intelligent comments as to why this treatment is superior to the Northwest Bio's (NWBO) DCVax (currently in phase 3 that is almost completed)? Thanks.
  • Large Jan $10 call buyer, over 3K; very bold; if just a hedge, why so far out in time? They could have obtained the Oct $10 calls for ONE THIRD THE PRICE of those bought in January. Very interesting.
  • The Rob obsession by George continues......LOL! Many on here don't even know who that is, but I bet you that he is no analyst, & probably not sold a car in decades (if he ever did that); don't get George's motivation, except that he is mad at Rob....did Rob make his investment bad or what? For all the time & money he spent attacking that dude, he could have bought a new boat or something huh? So ignorant, and it does not make anyone else sell here, since most are not so stupid. The stock is down cause "all" nearly biotech is down today, and it's on super low volume.....both ZIOP & XON have nearly exact volume - just noticed that. But obviously George will never ever get a life & never tell you his picks ahead of time.....lol.
  • So many better names in bio land to short & these obsessed mongrels keep trying on Ziopharm, even though less than a buck off of its lows; can you believe? So damn dumb!
  • at $6 per share zip is valued at 800 mill ??? with only 80 mill in bank ?

    prepare for another offering eoy.. and yes still at $5 ish ..
  • It is comical, dropping on the lowest possible volume, after all them calls bought; and you have to realize that the XBI is getting manipulated down pretty heavy to low of the day here.
  • This guy George is on every message board out there (under multiple names) & every one with a brain has him on ignore; he might as well talk to a wall, & I bet he does....lol.
  • Entire sector down. Perfect buying prices.
  • Yep, controlled by crooks (at times) it seems = you see huge call buying one day & the next MMs drive price down; so typical. Buy shares, not gamble on mega calls, even to hedge. #Dumb
  • I think is time to create a GoFundMe page, to raise money for its funeral.
  • Lots of lonely bears stalking all these message boards huh? If you so confident Ziopharm is going to fail why do you have spend so much time trying to talk people into selling???? (Am I right?)
  • Next important date???/
  • What's ZamdTard going to do with all of those ZIOP shares he bought for $10? He bought the majority of his shares well over $9 and a large chunk at $10. That bag holder is going to take a beating like a drum.
  • Once again weak lunatic idiotic sellers not making any money; you not getting my shares you nuts!
  • The lowest of low volume hits the bid lower under $6, but stock is basically tracking the XBI index; low volume seller not making any $$$.